Anti-NMI antibody (1-100aa) [SRM13153] (STJ11107883)

SKU:
STJ11107883
£0.00
Processing The item has been added

Host: Rabbit
Applications: WB/IHC-P/ELISA
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Clonality : Monoclonal
Clone ID : SRM13153
Conjugation: Unconjugated
Isotype: IgG
Formulation: PBS with 0.02% Sodium Azide, 0.05% BSA, 50% Glycerol, pH7.3.
Purification: Affinity purification
Concentration: Lot specific
Dilution Range: WB, 1:500-1:1000
IHC-P, 1:100-1:400
ELISA, Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements.
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: NMI
Gene ID: 9111
Uniprot ID: NMI_HUMAN
Immunogen Region: 1-100aa
Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 1-100 of human NMI (NP_004679.2).
Immunogen Sequence: Human
Post Translational Modifications Ubiquitinated. 'Lys-63'-linked ubiquitination by TRIM21 promotes interaction with IFI35 and inhibits virus-triggered type I IFN-beta production.
Function Acts as a signaling pathway regulator involved in innate immune system response. In response to interleukin 2/IL2 and interferon IFN-gamma/IFNG, interacts with signal transducer and activator of transcription/STAT which activate the transcription of downstream genes involved in a multitude of signals for development and homeostasis. Enhances the recruitment of CBP/p300 coactivators to STAT1 and STAT5, resulting in increased STAT1- and STAT5-dependent transcription. In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator IFI35 to regulate immune response.the complex formation prevents proteasome-mediated degradation of IFI35. In complex with IFI35, inhibits virus-triggered type I IFN-beta production when ubiquitinated by ubiquitin-protein ligase TRIM21. In complex with IFI35, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries. Negatively regulates virus-triggered type I interferon/IFN production by inducing proteosome-dependent degradation of IRF7, a transcriptional regulator of type I IFN, thereby interfering with cellular antiviral responses. Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation, when actively released by macrophage to the extracellular space during cell injury or pathogen invasion. Macrophage-secreted NMI activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 binding and activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of pro-inflammatory cytokines.
Protein Name N-Myc-Interactor
Nmi
N-Myc And Stat Interactor
Database Links Reactome: R-HSA-9692916
Cellular Localisation Cytoplasm
Nucleus
Secreted
Cytoplasmic Nmi Localizes In Punctate Granular Structures
Nuclear Localization Increased Following Ifn-Alpha Treatment
Extracelullar Following Secretion By Macrophage
Alternative Antibody Names Anti-N-Myc-Interactor antibody
Anti-Nmi antibody
Anti-N-Myc And Stat Interactor antibody
Anti-NMI antibody

Information sourced from Uniprot.org